

10/505,476

=> file caplus

FILE 'CAPLUS' ENTERED AT 15:28:17 ON 22 FEB 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Feb 2006 VOL 144 ISS 9


FILE LAST UPDATED: 21 Feb 2006 (20060221/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d que

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 7 SEA FILE=REGISTRY SSS FUL L1

L4 3 SEA FILE=CAPLUS L3

=> d l4 1-3 ibib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:757699 CAPLUS

DOCUMENT NUMBER: 139:276898

TITLE: Preparation of imidazolinyipyridone derivatives as NPY receptor antagonists

INVENTOR(S): Sato, Nagaaki; Nagase, Tsuyoshi; Nagai, Keita; Ando, Makoto; Kanatani, Akio

PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|-------|-----------------|-------|
| ----- | ---- | ----- | ----- | ----- |

WO 2003078422 A1 20030925 WO 2003-JP3115 20030314
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2479141 AA 20030925 CA 2003-2479141 20030314
AU 2003221394 A1 20030929 AU 2003-221394 20030314
EP 1486497 A1 20041215 EP 2003-710371 20030314
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2005154025 A1 20050714 US 2003-505476 20030314
PRIORITY APPLN. INFO.: JP 2002-73120 A 20020315
WO 2003-JP3115 W 20030314
OTHER SOURCE(S): MARPAT 139:276898
GI



AB The title compds. with general formula of I [wherein R1 = H, halo, CN, alkyl, haloalkyl, OH, alkoxy, or aralkyloxy; R2 and R3 = independently H, halo, or haloalkyl; R4 and R5 = independently H or halo; with exclusions] and salts thereof are prepared as neuropeptide Y (NPY) receptor antagonists. I are useful as a therapeutic agent for various diseases in which NPY participates, e.g., overeating, obesity, or diabetes (no data). Thus, the compound II was prepared in a multi-step synthesis. II showed IC50 of 2.8 nM against human NPY. Formulations containing I as an active ingredient were also described.

IT **604773-87-7P 604773-89-9P 604773-91-3P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of imidazolinylpyridone derivs. as NPY receptor antagonists)

RN 604773-87-7 CAPLUS

CN 2(1H)-Pyridinone, 6-[(4R,5S)-4-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/505,476



RN 604773-89-9 CAPLUS

CN 2(1H)-Pyridinone, 5-fluoro-6-[(4S,5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 604773-91-3 CAPLUS

CN 2(1H)-Pyridinone, 6-[(5S)-4-(4-fluorophenyl)-4,5-dihydro-5-methyl-4-[6-(trifluoromethyl)-3-pyridinyl]-1H-imidazol-2-yl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 604773-95-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of imidazolinyipyridone derivs. as NPY receptor antagonists)

RN 604773-95-7 CAPLUS

CN Pyridine, 6-[(5S)-4-(4-fluorophenyl)-4,5-dihydro-5-methyl-4-[6-(trifluoromethyl)-3-pyridinyl]-1H-imidazol-2-yl]-3-methyl-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:132359 CAPLUS

DOCUMENT NUMBER: 138:187642

TITLE: Preparation of pyridyl-1,2-ethanediamines as intermediates for NPY receptor antagonists

INVENTOR(S): Takahashi, Hirofumi; Sato, Nagaaki; Nagai, Keita; Jitsuoka, Makoto; Uchiito, Shiho; Fukami, Takehiro

PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 55 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|----------|
| JP 2003048875 | A2 | 20030221 | JP 2001-233519 | 20010801 |
| PRIORITY APPLN. INFO.: | | | JP 2001-233519 | 20010801 |

OTHER SOURCE(S): MARPAT 138:187642

AB The compds. NH₂CR₁pAr₁pCR₂pR₃pNH₂ [Ar₁p = (un)substituted aryl, heteroaryl; R₁p = lower cycloalkyl, (un)substituted aryl, heteroaryl; R₂p, R₃p = H, lower cycloalkyl, lower alkenyl, (un)substituted lower alkyl; if R₂p = R₃p = H, then both of Ar₁p and R₁p are not Ph; if R₂p = H, R₃p = Me, iso-Pr, iso-Bu, tert-Bu, then both of Ar₁p and R₁p are not tert-methoxyphenyl] are prepared by reaction of RS(O)N:CAr₁pCR₂pR₃pNHP (Ar₁, R₂p, R₃p = same as above; R = bulky group; P = NH₂-protecting group) with organic metal compds. having R₁p group (R₁p = same as above) and deprotection of RS(O)NHCAr₁pR₁pCR₂pR₃pNHP (Ar₁, P, R, R₁p, R₂p, R₃p = same as above). The compds. are prepared from RS(O)N:CR₁pCR₂pR₃pNHP (P, R, R₁p, R₂p, R₃p = same as above) with metal compds. containing Ar₁p group (Ar₁p = same as above). The compds. are intermediates for imidazoline NPY receptor antagonists as antiobesity agents, antidiabetic agents, and polyphagy treatment agents. Tert-Bu N-[(1S)-2-[(R)-(tert-butylsulfinyl)imino]-2-(4-fluorophenyl)-1-methylethyl]carbamate (200 mg) was reacted with 2-fluoro-5-pyridyllithium in PhMe-hexane in the presence of Et₃Al at -78° for 1 h to give 175 mg tert-Bu N-[(1S,2S)-2-[(R)-(tert-butylsulfinyl)amino]-2-(4-fluorophenyl)-2-(6-fluoro-3-pyridyl)-1-methylethyl]carbamate, which was treated with HCl in dioxane at room temperature for 15 min to give (1S,2S)-1-(4-fluorophenyl)-1-(6-fluoro-3-pyridyl)-1,2-propanediamine. 2-(3-Cyanophenyl)-4,4-bis(3-fluorophenyl)-2-imidazoline

10/505,476

showed IC₅₀ of 2.3 nM for inhibiting the binding of [125I] peptide YY to human NPY receptor.

IT 357926-26-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridylethanediamines by addition of sulfinyliminoethylamines and deprotection as intermediates for imidazoline NPY receptor antagonists)

RN 357926-26-2 CAPLUS

CN 2(1H)-Pyridinone, 6-[(5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:636055 CAPLUS

DOCUMENT NUMBER: 135:211050

TITLE: Preparation of imidazoline compounds as antagonists of neuropeptide Y receptor

INVENTOR(S): Sato, Nagaaki; Okamoto, Osamu; Jitsuoka, Makoto; Nagai, Keita; Kanatani, Akio; Ishihara, Akane; Ishii, Yasuyuki; Fukami, Takehiro

PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 137 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:





| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2001062738 | A1 | 20010830 | WO 2001-JP1312 | 20010222 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2400659 | AA | 20010830 | CA 2001-2400659 | 20010222 |
| AU 2001034128 | A5 | 20010903 | AU 2001-34128 | 20010222 |
| EP 1264826 | A1 | 20021211 | EP 2001-906215 | 20010222 |
| EP 1264826 | B1 | 20050330 | | |

10/505,476

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

| | | | | |
|------------------------|----|----------|-----------------|------------|
| AT 292119 | E | 20050415 | AT 2001-906215 | 20010222 |
| ES 2236178 | T3 | 20050716 | ES 2001-1906215 | 20010222 |
| US 2003158418 | A1 | 20030821 | US 2002-204267 | 20020925 |
| PRIORITY APPLN. INFO.: | | | JP 2000-45042 | A 20000222 |
| | | | WO 2001-JP1312 | W 20010222 |

OTHER SOURCE(S): MARPAT 135:211050
 GI



AB Compds. represented by the general formula (I) [wherein Ar1, Ar2, Ar3 = aryl or heteroaryl each optionally having substituents selected from cyano, halo, NO2, lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower cycloalkyl-lower alkyl, lower alkenyl, lower alkylamino, di-lower alkylamino, lower alkanoylamino, lower alkylsulfonylamino, arylsulfonylamino, HO, lower alkoxy, halo-lower alkoxy, aryloxy, heteroaryloxy, lower alkylthio, CO2H, CHO, lower alkanoyl, lower alkoxy, carbonyl, CONH2, lower alkylcarbonyl, di-lower alkylcarbonyl, lower alkylsulfonyl, arylsulfonyl, aryl, and heteroaryl; n = 0,1; R1 = lower cycloalkyl, Ar3, Q, Q1, Q2; R1, R2 = H, lower cycloalkyl, lower alkenyl, lower alkyl optionally having substituents selected from halo, lower alkylamino, di-lower alkylamino, lower alkanoylamino, HO, lower alkoxy, CHO, lower alkoxy, carbonyl, lower alkylcarbonyl, and di-lower alkylcarbonyl; wherein R10 = R11 = H, or R10 and R11 together represents oxo; X, Y = CH2, CH2CH2, NR12 (wherein R12 = H, lower alkyl), O, S; Z = CH, N; with the proviso that when R2 and R3 are simultaneously hydrogen, Ar1, Ar2 and R1 do not simultaneously represent unsubstituted phenyl] or salts or esters thereof are prepared. These compds. are useful as therapeutic agents for treating various neuropeptide Y (NPY)-related diseases, for example, circulatory diseases including hypertension, kidney diseases, cardiac diseases, vasospasm, and arteriosclerosis; central nervous system diseases including hyperphagia, depression, anxiety, convulsion, epilepsy, dementia, pain, alc. dependence, and withdrawal symptoms due to abstinence from drugs; metabolic diseases including obesity, diabetes, hormonal disorders, hypercholesterolemia, and hyperlipidemia; sexual dysfunction and reproductive function disorders; digestive diseases including enterokinetic disorders; respiratory diseases; inflammation; or glaucoma. Thus, 46.5 mg 2,4-dicyanopyridine and 24 mg ytterbium trifluoromethanesulfonate were added to a solution of 100 mg (2S)-1-(4-fluorophenyl)-1-(6-fluoro-3-pyridyl)-1,2-propanediamine in 0.25 mL PhMe and stirred at 100° for 5 h to give 106 mg optically active (5S)-2-(4-cyano-2-pyridyl)-4-(4-fluorophenyl)-4-(6-fluoro-3-

10/505,476

pyridyl)-5-methyl-2-imidazolidine (II). II in vitro showed IC₅₀ of 1.7 nM for inhibiting the binding of [125I]peptide YY to human NPY receptor. Tablet formulations containing 2-(3-cyanophenyl)-4,4-bis(4-fluorophenyl)-2-imidazolidine were prepared


IT 357926-26-2P 357927-31-2P 357927-32-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazoline compds. as antagonists of neuropeptide Y receptor)

RN 357926-26-2 CAPLUS

CN 2(1H)-Pyridinone, 6-[(5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 357927-31-2 CAPLUS

CN 2(1H)-Pyridinone, 6-[(4S,5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 357927-32-3 CAPLUS

CN 2(1H)-Pyridinone, 6-[(4R,5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/505,476



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatall

FILE 'USPATFULL' ENTERED AT 15:28:59 ON 22 FEB 2006


CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:28:59 ON 22 FEB 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 7 SEA FILE=REGISTRY SSS FUL L1

L5 2 SEA L3

=> d l5 1-2 ibib abs hitstr

L5 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2005:177944 USPATFULL

TITLE: Novel pyridone derivatives

INVENTOR(S): Sato, Nagaaki, Tsukuba-shi, JAPAN
Nagase, Tsuyoshi, Tsukuba-shi, JAPAN
Nagai, Keita, Tsukuba-shi, JAPAN
Ando, Makoto, Tsukuba-shi, JAPAN
Kanatani, Akio, Tsukuba-shi, JAPAN

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2005154025 | A1 | 20050714 |
| APPLICATION INFO.: | US 2003-505476 | A1 | 20030314 (10) |
| | WO 2003-JP3115 | | 20030314 |

| NUMBER | DATE |
|--------|-------|
| ----- | ----- |

PRIORITY INFORMATION: JP 2003-2002073120 20020315
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W.,
 SUITE 800, WASHINGTON, DC, 20006-1021, US
 NUMBER OF CLAIMS: 20
 EXEMPLARY CLAIM: 1
 LINE COUNT: 1329


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula (I): ##STR1## wherein R.sup.1 is hydrogen, halogen, cyano, lower alkyl, halo-lower alkyl, hydroxy, lower alkoxy or aralkyloxy; R.sup.2 and R.sup.3 are each independently hydrogen, halogen or halo-lower alkyl; and R.sup.4 and R are each independently hydrogen or halogen, is useful as a pharmaceutical composition for the treatment of various diseases related to NPY, for example, cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, etc., nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorders, inflammatory diseases or glaucoma, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 604773-87-7P 604773-89-9P 604773-91-3P
 (drug candidate; preparation of imidazolinyipyridone derivs. as NPY receptor antagonists)
 RN 604773-87-7 USPATFULL
 CN 2(1H)-Pyridinone, 6-[(4R,5S)-4-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 604773-89-9 USPATFULL
 CN 2(1H)-Pyridinone, 5-fluoro-6-[(4S,5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/505,476



RN 604773-91-3 USPATFULL

CN 2(1H)-Pyridinone, 6-[(5S)-4-(4-fluorophenyl)-4,5-dihydro-5-methyl-4-[6-(trifluoromethyl)-3-pyridinyl]-1H-imidazol-2-yl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 604773-95-7P

(intermediate; preparation of imidazolinyldipyrone derivs. as NPY receptor antagonists)

RN 604773-95-7 USPATFULL

CN Pyridine, 6-[(5S)-4-(4-fluorophenyl)-4,5-dihydro-5-methyl-4-[6-(trifluoromethyl)-3-pyridinyl]-1H-imidazol-2-yl]-3-methyl-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2003:226605 USPATFULL

TITLE: Novel imidazonline compounds

INVENTOR(S): Sato, Nagaaki, Tsukuba-shi, JAPAN
 Okamoto, Osamu, Tsukuba-shi, JAPAN
 Jitsuoka, Makoto, Tsukuba-shi, JAPAN
 Nagai, Keita, Tsukuba-shi, JAPAN
 Kanatani, Akio, Tsukuba-shi, JAPAN
 Ishihara, Akane, Tsukuba-shi, JAPAN
 Ishii, Yasuyuki, Tsukuba-shi, JAPAN
 Fukami, Takehiro, Tsukuba-shi, JAPAN

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2003158418 | A1 | 20030821 |
| APPLICATION INFO.: | US 2002-204267 | A1 | 20020925 (10) |
| | WO 2001-JP1312 | | 20010222 |

| | NUMBER | DATE |
|--|---|----------|
| PRIORITY INFORMATION: | JP 2000-45042 | 20000222 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021 | |
| NUMBER OF CLAIMS: | 23 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 3579 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | |
| AB | Compounds represented by the general formula (I): ##STR1## | |

wherein Ar.sup.1 and Ar.sup.2 are each aryl or heteroaryl; R.sup.1 is lower cycloalkyl, --Ar.sup.3, or a group of the general formula (a), (b) or (c): ##STR2##

and R.sup.2 and R.sup.3 are each hydrogen, lower cycloalkyl, lower alkenyl, or optionally substituted lower alkyl (with the proviso that when R.sup.2 and R.sup.3 are simultaneously hydrogen, Ar.sup.1, Ar.sup.2 and R.sup.1 do not simultaneously represent unsubstituted phenyl). The compounds are useful as treating agents for various NPY-related diseases, for example, circulatory diseases including hypertension, kidney diseases, cardiac diseases, vasospasm and arteriosclerosis; central nervous system diseases including hyperphagia, depression, anxiety, convulsion, epilepsy, dementia, pain, alcohol dependence, and withdrawal symptoms due to abstinence from drugs; metabolic diseases including obesity, diabetes, hormonal disorders, hypercholesterolemia, and hyperlipidemia; sexual dysfunction and reproductive function disorders; digestive diseases including enterokinetic disorders; respiratory diseases; inflammation; or glaucoma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 357926-26-2P 357927-31-2P 357927-32-3P


(preparation of imidazoline compds. as antagonists of neuropeptide Y receptor)

RN 357926-26-2 USPATFULL

CN 2(1H)-Pyridinone, 6-[(5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/505,476



RN 357927-31-2 USPATFULL

CN 2(1H)-Pyridinone, 6-[(4S,5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 357927-32-3 USPATFULL

CN 2(1H)-Pyridinone, 6-[(4R,5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>